Nuvation Bio Inc (NYSE: NUVB), a New York-based global oncology company involved in cancer treatment, announced on Tuesday that David Hung, MD, founder, president, and chief executive officer of Nuvation Bio, and Philippe Sauvage, its chief financial officer, will participate in a fireside chat at the Jefferies Global Healthcare Conference in London on Tuesday, 17 November 2026, at 2:30 p.m. GMT.
A live webcast of the fireside chat will be available on the Investor Relations section of the Nuvation Bio website. An archived recording will be available for 90 days following each event.
INOVIO prices public offering of approximately USD75m
First patient dosed in Phase 1 trial of Transgene and BioInvent's BT-001 for rectal cancer
Elicera Therapeutics secures Chinese patent allowance for ELC-401
CHOSA Oncology signs US laboratory agreement for Platin-DRP commercialisation
BeOne Medicines wins FDA Priority Review for BRUKINSA combination in first-line mantle cell lymphoma
Pentixapharm advances preparationsfor Phase 3 PANDA study
CStone and Kimia Therapeutics collaborate to advance oncology drug candidate
Vivesto secures US orphan drug designation for Cantrixil in acute myeloid leukemia
Lytix Biopharma's ruxotemitide combination meets primary endpoint in Phase II melanoma trial
INOVIO's VOCERYQ receives US FDA accelerated approval to reduce surgery frequency in adults with RRP
Phrontline Biopharma reports preliminary safety and antitumour activity for TJ101
TME Pharma signs exclusive negotiation agreement with Japan's TMS for NOX-A12 rights
Evogene targets acute graft-versus-host disease for AI-driven drug discovery programme
Genmab reports 50% reduction in risk of death in Phase 3 head and neck cancer trial
Novocure and Verastem to evaluate combination therapy for pancreatic cancer